Bioceltix S.A. Logo

Bioceltix S.A.

Developing 'off-the-shelf' stem cell therapies for diseases in companion animals.

BCX | WAR

Overview

Corporate Details

ISIN(s):
PLBCLTX00019 (+1 more)
LEI:
259400QZD5JYK8SLZU51
Country:
Poland
Address:
Wrocław Bierutowska 57-59/BUD.III, 51-317 Wrocław
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bioceltix S.A. is a biotechnology company specializing in the development of innovative biological medicines for the veterinary sector. The company focuses on creating 'off-the-shelf' biopharmaceuticals derived from mesenchymal stem cells for the treatment of diseases in companion animals. Utilizing its proprietary, scalable ALLO-BCLX technology, Bioceltix develops allogeneic stem cell therapies targeting common conditions, including degenerative joint disease in dogs and cats. The company's operations span from research and development to establishing manufacturing capabilities for its advanced veterinary therapeutics.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-05-07 18:29
Declaration of Voting Results & Voting Rights Announcements
Informacja o liczbie akcji i głosów
Polish 74.3 KB
2024-05-07 18:29
Governance Information
Klauzula informacyjna o przetwarzaniu danych osobowych
Polish 174.2 KB
2024-05-07 18:29
Proxy Solicitation & Information Statement
Formularz głosowania przez pełnomocnika
Polish 160.9 KB
2024-05-07 18:29
Proxy Solicitation & Information Statement
Formularze pełnomocnictwa
Polish 115.1 KB
2024-05-07 18:29
Registration Form
Zestawienie zmian statutu
Polish 86.8 KB
2024-05-07 18:29
Share Issue/Capital Change
Opinia Zarządu
Polish 73.1 KB
2024-05-07 18:29
Post-Annual General Meeting Information
Projekty uchwał wraz z uzasadnieniem
Polish 148.9 KB
2024-05-07 18:29
Pre-Annual General Meeting Information
Ogłoszenie o zwołaniu NWZ
Polish 145.2 KB
2024-05-07 18:29
Pre-Annual General Meeting Information
Zwołanie NWZ na dzień 3 czerwca 2024 roku - Content (PL)
Polish 2.1 KB
2024-05-07 17:38
Share Issue/Capital Change
Przyjęcie planu budowy wielkoskalowej wytwórni komórek macierzystych i sposobu …
Polish 5.4 KB
2024-04-26 17:12
Annual / Quarterly Financial Statement
Podpisy do opinii biegłego rewidenta z badania Sprawozdania Finansowego Biocelt…
Polish 10.3 KB
2024-04-26 17:12
Annual / Quarterly Financial Statement
Opinia biegłego rewidenta z badania Sprawozdania Finansowego Bioceltix S.A. za …
Polish 2.9 MB
2024-04-26 17:12
Annual / Quarterly Financial Statement
Podpisy do Raportu okresowego rocznego Bioceltix S.A. za rok 2023
Polish 20.9 KB
2024-04-26 17:12
Annual Report
Raport okresowy roczny Bioceltix S.A. za rok 2023
Polish 17.3 MB
2024-04-26 17:12
Annual Report
Podpisy do Sprawozdania z Działalności Bioceltix S.A. za okres sprawozdawczy za…
Polish 20.9 KB

Automate Your Workflow. Get a real-time feed of all Bioceltix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Bioceltix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.